Misbruk av pregabalin

Tidsskrift for den Norske Laegeforening

Volumn 130, Issue 17, 2010, Pages 1703-1704

  Bramness, Jørgen G ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; PREGABALIN;

ADDICTION; HUMAN; LETTER;

ANALGESICS; ANTICONVULSANTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 77956921611     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.10.0834     Document Type: Letter

References (9)

1. LaRoche S. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007; 13: 133-9.
2. Mula M, Pini S, Cassano G. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27: 263-72.
3. Jensen T, Finnerup N. Management of neuropathic pain. Curr Opin Support Palliat Care 2007; 1: 126-31.
4. Holtedahl R. Tvilsom dokumentasjon av effekten av pregabalin ved fibromyalgi. Tidsskr Nor Legeforen 2010; 130: 1032-6.
5. Chalabianloo F, Schjott J. Pregabalin og misbrukspotensial. Tidsskr Nor Legeforen 2009; 129: 186-7.
6. Bramness JG, Sandvik P, Engeland A et al. Does pregabalin (Lyrica((R))) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol 2010; e-publisert 23.4.
7. Grosshans M, Mutschler J, Hermann D et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 2010; 167: 869.
8. Schwan S, Sundstrom A, Stjernberg E. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010; 66: 947-53.
9. Bramness J, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe. Nor J Epidemiol 2008; 18: 167-72.